Article(id=1326654734817145096, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326654653699306189, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2025.04.012, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1726070400000, receivedDateStr=2024-09-12, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794228736833, onlineDateStr=2026-11-09, pubDate=1744214400000, pubDateStr=2025-04-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794228736833, onlineIssueDateStr=2026-11-09, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794228736833, creator=13701087609, updateTime=1794228736833, updator=13701087609, issue=Issue{id=1326654653699306189, tenantId=1146029695717560320, journalId=1319690329412173987, year='2025', volume='46', issue='4', pageStart='315', pageEnd='428', issueExtLink='null', onlineDate='null', pubDate='1744214400000', pubDateStr='2025-04-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794228717492, creator='13701087609', updateTime=1794273058269, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1326840632833848267, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326654653699306189, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1326840632838042572, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326654653699306189, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=393, endPage=400, ext={EN=ArticleExt(id=1326654735031054601, articleId=1326654734817145096, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Mining and analysis of adverse event signals of sacituzumab govitecan based on the Food and Drug Administration adverse event reporting system database in the United States, columnId=1325221089055486019, journalTitle=World Clinical Drug, columnName=Article, runingTitle=null, highlight=null, articleAbstract=
Objective

To explore and analyze the adverse drug event (ADE) signals of sacituzumab govitecan in the database of the Food and Drug Administration adverse event reporting system (FAERS) of the United States.

Method

Adverse event reports related to sacituzumab govitecan from the second quarter of 2020 to the first quarter of 2024 were selected from the United States FAERS database. The reporting odds ratio method in the ratio imbalance method in combination with the Bayesian confidence propagation neural network (BCPNN) method were used to conduct data mining and analysis.

Result

After screening, a total of 3 085 ADE reports were obtained. Among them, female patients accounted for a relatively large proportion (86.09%), and the age group was mainly 45~64 years old (25.35%). The reporting country was mainly the United States (34.20%). The outcome was mainly composed of mortality rate (26.65%) and hospitalization rate (28.75%). There were 145 positive signals related to ADE involving 26 systemic organ classifications.The frequency of occurrence of ADE signals was basically consistent with the instructions. The instructions do not mention serious adverse reactions such as hemorrhagic diarrhea, paralytic intestinal obstruction, large intestine perforation, febrile bone marrow aplasia and bone marrow failure, etc..

Conclusion

When doctors us sacituzumab govitecan in clinical practice, it is necessary to conduct an assessment for the patient's medication use. During the treatment period, new adverse reactions should be vigilant, and timely intervention should be carried out when abnormalities are detected.

, authors=Huiyu XU1, Yaodong YAN1, Ruizhe QI2, *, authorsList=Huiyu XU, Yaodong YAN, Ruizhe QI, authorCompany=null, correspAuthors=Ruizhe QI, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1326654735509205258, articleId=1326654734817145096, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=基于美国FAERS数据库中戈沙妥珠单抗的药物不良事件信号挖掘与分析, columnId=1325221089235841093, journalTitle=世界临床药物, columnName=研究论文, runingTitle=null, highlight=null, articleAbstract=
目的

探讨美国食品和药品管理局不良事件报告系统(Food and Drug Administration adverse event reporting system,FAERS)数据库中戈沙妥珠单抗的药物不良事件(adverse drug event,ADE)信号进行挖掘分析。

方法

选择美国FAERS数据库中2020年第2季度至2024年第1季度的戈沙妥珠单抗相关ADE报告。运用比值失衡法中的报告比值比法联合贝叶斯可信区间递进神经网络法(bayesian confidence propagation neural network,BCPNN)进行数据挖掘及分析。

结果

筛选后,共获得3 085例ADE报告。其中女性患者占比较多(86.09%),年龄人群以45~64岁(25.35%)为主。上报国家以美国(34.20%)为主;转归结果以死亡(26.65%)和住院(28.75%)为主。有145个与ADE相关的阳性信号涉及26个系统器官分类。ADE信号发生频次较高的与说明书基本一致。说明书中未提及严重不良反应有出血性腹泻、麻痹性肠梗阻、大肠穿孔,发热性骨髓再生障碍以及骨髓功能衰竭等。

结论

医生临床使用戈沙妥珠单抗时应做好患者用药评估,治疗期间应警惕新的不良反应的发生,当发现异常时应及时干预。

, authors=徐慧钰1, 颜耀东1, 祁瑞哲2, *, authorsList=徐慧钰, 颜耀东, 祁瑞哲, authorCompany=null, correspAuthors=祁瑞哲, authorNote=

徐慧钰,主管药师,研究方向:临床药学。

, correspAuthorsNote=
祁瑞哲,副主任药师,研究方向:临床药学。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=NbHGZ11F+8U5AvRhDE6Qtg==, magXml=5EWTWuIPw9OjcORgNxQKrA==, pdfUrl=null, pdf=UBwMhLy1fnoeOvUWbrp2rQ==, pdfFileSize=1266108, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=lxbDHXLWfstT0d0qQwhyTw==, mapNumber=null, fund=null)}, authors=[Author(id=1326654735937024274, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326654736008327444, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, authorId=1326654735937024274, language=EN, stringName=Huiyu XU, firstName=Huiyu, middleName=null, lastName=XU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Pharmacy, Beijing Jiangong Hospital, Beijing 100054, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326654736226431254, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, authorId=1326654735937024274, language=CN, stringName=徐慧钰, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.北京市健宫医院药剂科,北京 100054, bio={"content":"

徐慧钰,主管药师,研究方向:临床药学。

"}, bioImg=null, bioContent=

徐慧钰,主管药师,研究方向:临床药学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326654735744086283, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, xref=1., ext=[AuthorCompanyExt(id=1326654735769252108, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, companyId=1326654735744086283, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Beijing Jiangong Hospital, Beijing 100054, China), AuthorCompanyExt(id=1326654735781835021, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, companyId=1326654735744086283, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.北京市健宫医院药剂科,北京 100054)])]), Author(id=1326654736343871768, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326654736444535067, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, authorId=1326654736343871768, language=EN, stringName=Yaodong YAN, firstName=Yaodong, middleName=null, lastName=YAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Pharmacy, Beijing Jiangong Hospital, Beijing 100054, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326654736524226844, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, authorId=1326654736343871768, language=CN, stringName=颜耀东, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.北京市健宫医院药剂科,北京 100054, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326654735744086283, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, xref=1., ext=[AuthorCompanyExt(id=1326654735769252108, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, companyId=1326654735744086283, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Beijing Jiangong Hospital, Beijing 100054, China), AuthorCompanyExt(id=1326654735781835021, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, companyId=1326654735744086283, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.北京市健宫医院药剂科,北京 100054)])]), Author(id=1326654736645861662, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326654736750719264, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, authorId=1326654736645861662, language=EN, stringName=Ruizhe QI, firstName=Ruizhe, middleName=null, lastName=QI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Department of Pharmacy, the Second Affiliated Hospital of Xingtai Medical College, Xingtai 054000, Hebei Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326654736868159777, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, authorId=1326654736645861662, language=CN, stringName=祁瑞哲, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.邢台医学院第二附属医院药学部,河北 邢台 054000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326654735840555278, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, xref=2., ext=[AuthorCompanyExt(id=1326654735848943887, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, companyId=1326654735840555278, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, the Second Affiliated Hospital of Xingtai Medical College, Xingtai 054000, Hebei Province, China), AuthorCompanyExt(id=1326654735857332496, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, companyId=1326654735840555278, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.邢台医学院第二附属医院药学部,河北 邢台 054000)])])], keywords=[Keyword(id=1326654736998183202, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, language=EN, orderNo=1, keyword=Food and Drug Administration adverse event reporting system), Keyword(id=1326654737065292067, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, language=EN, orderNo=2, keyword=sacituzumab govitecan), Keyword(id=1326654737291784484, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, language=EN, orderNo=3, keyword=adverse drug event), Keyword(id=1326654737346310437, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, language=EN, orderNo=4, keyword=signal mining), Keyword(id=1326654737430196518, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, language=CN, orderNo=1, keyword=美国食品和药品管理局不良事件报告系统), Keyword(id=1326654737518276903, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, language=CN, orderNo=2, keyword=戈沙妥珠单抗), Keyword(id=1326654737576997160, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, language=CN, orderNo=3, keyword=药物不良事件), Keyword(id=1326654737648300329, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, language=CN, orderNo=4, keyword=信号挖掘)], refs=[Reference(id=1326654738126450988, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=BARDIA A, MAYER IA, VAHDAT LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer[J]. N Engl J Med, 2019, 380(8): 741-751., articleTitle=null, refAbstract=null), Reference(id=1326654738193559853, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=TREROTOLA M, CANTANELLI P, GUERRA E, et al.Upregulation of Trop-2 quantitatively stimulates human cancer growth[J]. Oncogene, 2013, 32(2): 222-233., articleTitle=null, refAbstract=null), Reference(id=1326654738248085806, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=LIU W, DU Q, GUO Z, et al. Post-marketing safety surveillance of sacituzumab govitecan: an observational,pharmacovigilance study leveraging FAERS database[J].Front Pharmacol, 2023, 14: 1283247., articleTitle=null, refAbstract=null), Reference(id=1326654738323583279, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=尚鹏辉, 詹思延. 数据挖掘在药品不良反应信号检出和分析中的应用(下)——药物流行病学研究新方法系列讲座(三)[J]. 中国药物应用与监测, 2009, 6(3): 187-190., articleTitle=null, refAbstract=null), Reference(id=1326654738449412400, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=罗宝章, 钱轶峰, 叶小飞, 等. 药物不良反应信号检测方法的现状与展望[J]. 药学服务与研究, 2009, 9(4): 255-260., articleTitle=null, refAbstract=null), Reference(id=1326654738621378865, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=HOWARD FM, OLOPADE OI. Epidemiology of triple-negative breast cancer: a review[J]. Cancer J, 2021, 27(1):8-16., articleTitle=null, refAbstract=null), Reference(id=1326654738822705458, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=RUGO HS, TOLANEY SM, LOIRAT D, et al. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer[J]. NPJ Breast Cancer, 2022, 8(1): 98., articleTitle=null, refAbstract=null), Reference(id=1326654738881425715, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=GUI X, ZHAO J, DING L, et al. Assessing real-world safety concerns of sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system[J]. Front Oncol, 2023, 13: 1276976., articleTitle=null, refAbstract=null), Reference(id=1326654738935951668, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=RUGO HS, BARDIA A, MARME F, et al. Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer[J].J Clin Oncol, 2022, 40(29): 3365-3376., articleTitle=null, refAbstract=null), Reference(id=1326654738998866229, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=BARDIA A, TOLANEY SM, PUNIE K, et al. Biomarker analyses in the phase Ⅲ ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer[J]. Ann Oncol, 2021, 32(9):1148-1156., articleTitle=null, refAbstract=null), Reference(id=1326654739070169398, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=PRESCOTT AE, RAVINDRA A, JAVED A. Neutropenic enterocolitis: a rare complication of sacituzumab govitecan[J]. Case Rep Oncol, 2022, 15(2): 687-693., articleTitle=null, refAbstract=null), Reference(id=1326654739154055479, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=PUSZTASZERI MP, GENTA RM, CRYER BL. Drug-induced injury in the gastrointestinal tract: clinical and pathologic considerations[J]. Nat Clin Pract Gastroenterol Hepatol,2007, 4(8): 442-453., articleTitle=null, refAbstract=null), Reference(id=1326654739225358648, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=LI X, ZHANG L, HU S, et al. Postmarketing safety of sacituzumab govitecan: a pharmacovigilance study based on the FDA adverse event reporting system[J]. Clin Pharmacol Ther, 2024, 115(2): 256-268., articleTitle=null, refAbstract=null), Reference(id=1326654739288273209, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=XU B, MA F, WANG T, et al. A phase Ⅱb, single arm,multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments[J]. Int J Cancer. 2023, 152(10):2134-2144., articleTitle=null, refAbstract=null), Reference(id=1326654739342799162, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=DEAN L. Irinotecan therapy and UGT1A1 genotype[J].Biotechnology Information(US), 2012., articleTitle=null, refAbstract=null), Reference(id=1326654739401519419, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=KWEEKEL D, GUCHELAAR HJ, GELDERBLOM H.Clinical and pharmacogenetic factors associated with irinotecan toxicity[J]. Cancer Treat Rev, 2008, 34(7): 656-669., articleTitle=null, refAbstract=null), Reference(id=1326654739456045372, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=RIERA P, SALAZAR J, VIRGILI AC, et al. Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan-induced severe toxicity[J]. Br J Clin Pharmacol,2018, 84(6): 1389-1392., articleTitle=null, refAbstract=null), Reference(id=1326654739514765629, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=ETIENNE-GRIMALDI MC, BOYER JC, THOMAS F, et al. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice[J]. Fundam Clin Pharmaco, 2015, 29(3): 219-237., articleTitle=null, refAbstract=null), Reference(id=1326654739607040318, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=SIDAWAY P. Sacituzumab govitecan is safe and effective[J].Nat Rev Clin Oncol, 2021, 18(7): 400., articleTitle=null, refAbstract=null), Reference(id=1326654739665760575, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=OCEAN AJ, STARODUB AN, BARDIA A, et al.Sacituzumab govitecan(IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics[J]. Cancer, 2017,123(19): 3843-3854., articleTitle=null, refAbstract=null), Reference(id=1326654739854504256, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=HAN J, ZHANG J, ZHANG C. Irinotecan-induced steatohepatitis: current insights[J]. Front Oncol, 2021, 11:754891., articleTitle=null, refAbstract=null), Reference(id=1326654739997110593, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHU Z, SHEN G, LI J, et al. Incidence of antibody-drug conjugates-related pneumonitis in patients with solid tumors:a systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2023, 184: 103960., articleTitle=null, refAbstract=null), Reference(id=1326654740143911234, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=D'ARIENZO A, VERRAZZO A, PAGLIUCA M, et al.Toxicity profile of antibody-drug conjugates in breast cancer:practical considerations[J]. EClinicalMedicine, 2023, 62:102113., articleTitle=null, refAbstract=null), Reference(id=1326654740370403651, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=KAMATH AV, IYER S. Preclinical pharmacokinetic considerations for the development of antibody drug conjugates[J]. Pharm Res, 2015, 32(11): 3470-3479., articleTitle=null, refAbstract=null), Reference(id=1326654740513009988, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=LI C, MENON R, WALLES M, et al. Risk-based pharmacokinetic and drug-drug interaction characterization of antibody-drug conjugates in oncology clinical development:an international consortium for innovation and quality in pharmaceutical development perspective[J]. Clin Pharmacol Ther, 2022, 112(4): 754-769., articleTitle=null, refAbstract=null), Reference(id=1326654740689170757, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=JIANG Y, ZHANG C, ZHENG X, et al. Simultaneously screening multiple UGT1A1 inhibitors from Polygonum multiflorum root using ultrafiltration LC-MS[J]. Biomed Chromatogr. 2022, 36(4): e5300., articleTitle=null, refAbstract=null), Reference(id=1326654740823388486, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=LV X, XIA Y, FINEL M, et al. Recent progress and challenges in screening and characterization of UGT1A1 inhibitors[J].Acta Pharm Sin B, 2019, 9(2): 258-278., articleTitle=null, refAbstract=null), Reference(id=1326654742618550599, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=LIU XY, LV X, WANG P, et al. Inhibition of UGT1A1 by natural and synthetic flavonoids[J]. Int J Biol Macromo,2019, 126: 653-661., articleTitle=null, refAbstract=null)], funds=[Fund(id=1326654737837044010, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, awardId=2021ZC178, language=CN, fundingSource=新型抗肿瘤药物与患者异常超进展等预后的相关性研究(2021ZC178), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1326654735744086283, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, xref=1., ext=[AuthorCompanyExt(id=1326654735769252108, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, companyId=1326654735744086283, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Beijing Jiangong Hospital, Beijing 100054, China), AuthorCompanyExt(id=1326654735781835021, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, companyId=1326654735744086283, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.北京市健宫医院药剂科,北京 100054)]), AuthorCompany(id=1326654735840555278, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, xref=2., ext=[AuthorCompanyExt(id=1326654735848943887, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, companyId=1326654735840555278, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, the Second Affiliated Hospital of Xingtai Medical College, Xingtai 054000, Hebei Province, China), AuthorCompanyExt(id=1326654735857332496, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, companyId=1326654735840555278, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.邢台医学院第二附属医院药学部,河北 邢台 054000)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.04.012, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.04.012, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2025.04.012, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2025.04.012, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1744214400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
基于美国FAERS数据库中戈沙妥珠单抗的药物不良事件信号挖掘与分析
徐慧钰 1 , 颜耀东 1 , 祁瑞哲 2, *
世界临床药物 | 研究论文 2025,46(4): 393-400
收起
收藏切换
世界临床药物 |研究论文 2025 , 46 (4) : 393 -400
基于美国FAERS数据库中戈沙妥珠单抗的药物不良事件信号挖掘与分析
全屏
[Author(id=1326654735937024274, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326654736008327444, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, authorId=1326654735937024274, language=EN, stringName=Huiyu XU, firstName=Huiyu, middleName=null, lastName=XU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Pharmacy, Beijing Jiangong Hospital, Beijing 100054, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326654736226431254, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, authorId=1326654735937024274, language=CN, stringName=徐慧钰, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.北京市健宫医院药剂科,北京 100054, bio={"content":"

徐慧钰,主管药师,研究方向:临床药学。

"}, bioImg=null, bioContent=

徐慧钰,主管药师,研究方向:临床药学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326654735744086283, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, xref=1., ext=[AuthorCompanyExt(id=1326654735769252108, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, companyId=1326654735744086283, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Beijing Jiangong Hospital, Beijing 100054, China), AuthorCompanyExt(id=1326654735781835021, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, companyId=1326654735744086283, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.北京市健宫医院药剂科,北京 100054)])]), Author(id=1326654736343871768, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326654736444535067, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, authorId=1326654736343871768, language=EN, stringName=Yaodong YAN, firstName=Yaodong, middleName=null, lastName=YAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Pharmacy, Beijing Jiangong Hospital, Beijing 100054, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326654736524226844, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, authorId=1326654736343871768, language=CN, stringName=颜耀东, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.北京市健宫医院药剂科,北京 100054, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326654735744086283, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, xref=1., ext=[AuthorCompanyExt(id=1326654735769252108, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, companyId=1326654735744086283, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Beijing Jiangong Hospital, Beijing 100054, China), AuthorCompanyExt(id=1326654735781835021, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, companyId=1326654735744086283, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.北京市健宫医院药剂科,北京 100054)])]), Author(id=1326654736645861662, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326654736750719264, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, authorId=1326654736645861662, language=EN, stringName=Ruizhe QI, firstName=Ruizhe, middleName=null, lastName=QI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Department of Pharmacy, the Second Affiliated Hospital of Xingtai Medical College, Xingtai 054000, Hebei Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326654736868159777, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, authorId=1326654736645861662, language=CN, stringName=祁瑞哲, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.邢台医学院第二附属医院药学部,河北 邢台 054000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326654735840555278, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, xref=2., ext=[AuthorCompanyExt(id=1326654735848943887, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, companyId=1326654735840555278, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, the Second Affiliated Hospital of Xingtai Medical College, Xingtai 054000, Hebei Province, China), AuthorCompanyExt(id=1326654735857332496, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326654734817145096, companyId=1326654735840555278, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.邢台医学院第二附属医院药学部,河北 邢台 054000)])])]
徐慧钰1, 颜耀东1, 祁瑞哲2, *
作者信息
  • 1.北京市健宫医院药剂科,北京 100054
  • 2.邢台医学院第二附属医院药学部,河北 邢台 054000
通讯作者:
祁瑞哲,副主任药师,研究方向:临床药学。
作者简介:

徐慧钰,主管药师,研究方向:临床药学。

Mining and analysis of adverse event signals of sacituzumab govitecan based on the Food and Drug Administration adverse event reporting system database in the United States
Huiyu XU1, Yaodong YAN1, Ruizhe QI2, *
Affiliations
  • 1.Department of Pharmacy, Beijing Jiangong Hospital, Beijing 100054, China
  • 2.Department of Pharmacy, the Second Affiliated Hospital of Xingtai Medical College, Xingtai 054000, Hebei Province, China
出版时间: 2025-04-10 doi: 10.13683/j.wph.2025.04.012
文章导航
收藏切换
目的

探讨美国食品和药品管理局不良事件报告系统(Food and Drug Administration adverse event reporting system,FAERS)数据库中戈沙妥珠单抗的药物不良事件(adverse drug event,ADE)信号进行挖掘分析。

方法

选择美国FAERS数据库中2020年第2季度至2024年第1季度的戈沙妥珠单抗相关ADE报告。运用比值失衡法中的报告比值比法联合贝叶斯可信区间递进神经网络法(bayesian confidence propagation neural network,BCPNN)进行数据挖掘及分析。

结果

筛选后,共获得3 085例ADE报告。其中女性患者占比较多(86.09%),年龄人群以45~64岁(25.35%)为主。上报国家以美国(34.20%)为主;转归结果以死亡(26.65%)和住院(28.75%)为主。有145个与ADE相关的阳性信号涉及26个系统器官分类。ADE信号发生频次较高的与说明书基本一致。说明书中未提及严重不良反应有出血性腹泻、麻痹性肠梗阻、大肠穿孔,发热性骨髓再生障碍以及骨髓功能衰竭等。

结论

医生临床使用戈沙妥珠单抗时应做好患者用药评估,治疗期间应警惕新的不良反应的发生,当发现异常时应及时干预。

美国食品和药品管理局不良事件报告系统  /  戈沙妥珠单抗  /  药物不良事件  /  信号挖掘
Objective

To explore and analyze the adverse drug event (ADE) signals of sacituzumab govitecan in the database of the Food and Drug Administration adverse event reporting system (FAERS) of the United States.

Method

Adverse event reports related to sacituzumab govitecan from the second quarter of 2020 to the first quarter of 2024 were selected from the United States FAERS database. The reporting odds ratio method in the ratio imbalance method in combination with the Bayesian confidence propagation neural network (BCPNN) method were used to conduct data mining and analysis.

Result

After screening, a total of 3 085 ADE reports were obtained. Among them, female patients accounted for a relatively large proportion (86.09%), and the age group was mainly 45~64 years old (25.35%). The reporting country was mainly the United States (34.20%). The outcome was mainly composed of mortality rate (26.65%) and hospitalization rate (28.75%). There were 145 positive signals related to ADE involving 26 systemic organ classifications.The frequency of occurrence of ADE signals was basically consistent with the instructions. The instructions do not mention serious adverse reactions such as hemorrhagic diarrhea, paralytic intestinal obstruction, large intestine perforation, febrile bone marrow aplasia and bone marrow failure, etc..

Conclusion

When doctors us sacituzumab govitecan in clinical practice, it is necessary to conduct an assessment for the patient's medication use. During the treatment period, new adverse reactions should be vigilant, and timely intervention should be carried out when abnormalities are detected.

Food and Drug Administration adverse event reporting system  /  sacituzumab govitecan  /  adverse drug event  /  signal mining
徐慧钰, 颜耀东, 祁瑞哲. 基于美国FAERS数据库中戈沙妥珠单抗的药物不良事件信号挖掘与分析. 世界临床药物, 2025 , 46 (4) : 393 -400 . DOI: 10.13683/j.wph.2025.04.012
Huiyu XU, Yaodong YAN, Ruizhe QI. Mining and analysis of adverse event signals of sacituzumab govitecan based on the Food and Drug Administration adverse event reporting system database in the United States[J]. World Clinical Drug, 2025 , 46 (4) : 393 -400 . DOI: 10.13683/j.wph.2025.04.012
  • 新型抗肿瘤药物与患者异常超进展等预后的相关性研究(2021ZC178)
参考文献 引证文献
排序方式:
[1]
BARDIA A, MAYER IA, VAHDAT LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer[J]. N Engl J Med, 2019, 380(8): 741-751.
[2]
TREROTOLA M, CANTANELLI P, GUERRA E, et al.Upregulation of Trop-2 quantitatively stimulates human cancer growth[J]. Oncogene, 2013, 32(2): 222-233.
[3]
LIU W, DU Q, GUO Z, et al. Post-marketing safety surveillance of sacituzumab govitecan: an observational,pharmacovigilance study leveraging FAERS database[J].Front Pharmacol, 2023, 14: 1283247.
[4]
尚鹏辉, 詹思延. 数据挖掘在药品不良反应信号检出和分析中的应用(下)——药物流行病学研究新方法系列讲座(三)[J]. 中国药物应用与监测, 2009, 6(3): 187-190.
[5]
罗宝章, 钱轶峰, 叶小飞, 等. 药物不良反应信号检测方法的现状与展望[J]. 药学服务与研究, 2009, 9(4): 255-260.
[6]
HOWARD FM, OLOPADE OI. Epidemiology of triple-negative breast cancer: a review[J]. Cancer J, 2021, 27(1):8-16.
[7]
RUGO HS, TOLANEY SM, LOIRAT D, et al. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer[J]. NPJ Breast Cancer, 2022, 8(1): 98.
[8]
GUI X, ZHAO J, DING L, et al. Assessing real-world safety concerns of sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system[J]. Front Oncol, 2023, 13: 1276976.
[9]
RUGO HS, BARDIA A, MARME F, et al. Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer[J].J Clin Oncol, 2022, 40(29): 3365-3376.
[10]
BARDIA A, TOLANEY SM, PUNIE K, et al. Biomarker analyses in the phase Ⅲ ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer[J]. Ann Oncol, 2021, 32(9):1148-1156.
[11]
PRESCOTT AE, RAVINDRA A, JAVED A. Neutropenic enterocolitis: a rare complication of sacituzumab govitecan[J]. Case Rep Oncol, 2022, 15(2): 687-693.
[12]
PUSZTASZERI MP, GENTA RM, CRYER BL. Drug-induced injury in the gastrointestinal tract: clinical and pathologic considerations[J]. Nat Clin Pract Gastroenterol Hepatol,2007, 4(8): 442-453.
[13]
LI X, ZHANG L, HU S, et al. Postmarketing safety of sacituzumab govitecan: a pharmacovigilance study based on the FDA adverse event reporting system[J]. Clin Pharmacol Ther, 2024, 115(2): 256-268.
[14]
XU B, MA F, WANG T, et al. A phase Ⅱb, single arm,multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments[J]. Int J Cancer. 2023, 152(10):2134-2144.
[15]
DEAN L. Irinotecan therapy and UGT1A1 genotype[J].Biotechnology Information(US), 2012.
[16]
KWEEKEL D, GUCHELAAR HJ, GELDERBLOM H.Clinical and pharmacogenetic factors associated with irinotecan toxicity[J]. Cancer Treat Rev, 2008, 34(7): 656-669.
[17]
RIERA P, SALAZAR J, VIRGILI AC, et al. Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan-induced severe toxicity[J]. Br J Clin Pharmacol,2018, 84(6): 1389-1392.
[18]
ETIENNE-GRIMALDI MC, BOYER JC, THOMAS F, et al. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice[J]. Fundam Clin Pharmaco, 2015, 29(3): 219-237.
[19]
SIDAWAY P. Sacituzumab govitecan is safe and effective[J].Nat Rev Clin Oncol, 2021, 18(7): 400.
[20]
OCEAN AJ, STARODUB AN, BARDIA A, et al.Sacituzumab govitecan(IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics[J]. Cancer, 2017,123(19): 3843-3854.
[21]
HAN J, ZHANG J, ZHANG C. Irinotecan-induced steatohepatitis: current insights[J]. Front Oncol, 2021, 11:754891.
[22]
ZHU Z, SHEN G, LI J, et al. Incidence of antibody-drug conjugates-related pneumonitis in patients with solid tumors:a systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2023, 184: 103960.
[23]
D'ARIENZO A, VERRAZZO A, PAGLIUCA M, et al.Toxicity profile of antibody-drug conjugates in breast cancer:practical considerations[J]. EClinicalMedicine, 2023, 62:102113.
[24]
KAMATH AV, IYER S. Preclinical pharmacokinetic considerations for the development of antibody drug conjugates[J]. Pharm Res, 2015, 32(11): 3470-3479.
[25]
LI C, MENON R, WALLES M, et al. Risk-based pharmacokinetic and drug-drug interaction characterization of antibody-drug conjugates in oncology clinical development:an international consortium for innovation and quality in pharmaceutical development perspective[J]. Clin Pharmacol Ther, 2022, 112(4): 754-769.
[26]
JIANG Y, ZHANG C, ZHENG X, et al. Simultaneously screening multiple UGT1A1 inhibitors from Polygonum multiflorum root using ultrafiltration LC-MS[J]. Biomed Chromatogr. 2022, 36(4): e5300.
[27]
LV X, XIA Y, FINEL M, et al. Recent progress and challenges in screening and characterization of UGT1A1 inhibitors[J].Acta Pharm Sin B, 2019, 9(2): 258-278.
[28]
LIU XY, LV X, WANG P, et al. Inhibition of UGT1A1 by natural and synthetic flavonoids[J]. Int J Biol Macromo,2019, 126: 653-661.
2025年第46卷第4期
52
12
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2025.04.012
  • 接收时间:2024-09-12
  • 首发时间:2026-11-09
  • 出版时间:2025-04-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2024-09-12
基金
新型抗肿瘤药物与患者异常超进展等预后的相关性研究(2021ZC178)
作者信息
    1.北京市健宫医院药剂科,北京 100054
    2.邢台医学院第二附属医院药学部,河北 邢台 054000

通讯作者:

祁瑞哲,副主任药师,研究方向:临床药学。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.04.012
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏